

2016 Emerging Opportunities in the CA Tumor Marker Testing Market

https://marketpublishers.com/r/2B68CD28609EN.html

Date: October 2015

Pages: 278

Price: US\$ 4,360.00 (Single User License)

ID: 2B68CD28609EN

Abstracts

This report contains 278 pages, 40 tables and presents a detailed analysis of the CA 15-3/27.29, CA 19-9, and CA 125 testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers.

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.

Contains 278 pages and 40 tables



Contents

I. INTRODUCTION

II. CA TUMOR MARKERS WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

- A. CA Tumor Markers: Clinical Significance and Laboratory Practices
 - 1. CA 15-3/27.29
 - 2. CA 19-9
 - 3. CA
- B. Instrumentation Review And Market Needs
 - 1. Abbott AxSYM
 - 2. Abbott Architect c4000
 - 3. Abbott Architect i2000 Series
 - 4. Abbott Architect ci8200 System
 - 5. Beckman Coulter UniCel Series
 - 6. Beckman Coulter Access
 - 7. Binding Site ESP600
 - 8. bioMerieux Mini Vidas
 - 9. Carolina Chemistries BioLis 24i
 - 10. DiaSorin Liaison
 - 11. Horiba ABX Pentra
 - 12. Inverness DS2
 - 13. J&J Vitros ECi/ECiQ
 - 14. J&J Vitros 3600
 - 15. J&J Vitros 5600
 - 16. Olympus AU5400
 - 17. Olympus AU3000i
 - 18. Olympus AU2700
 - 19. Roche Modular Analytics
 - 20. Roche Cobas Integra
 - 21. Roche Cobas Integra 400 Plus
 - 22. Roche Elecsys
 - 23. Roche Cobas c311
 - 24. Siemens ADVIA Centaur
 - 25. Siemens Dimension
 - 26. Siemens Dimension RxL Max
 - 27. Siemens Dimension Vista
 - 28. Siemens Immulite



- 29. Siemens Stratus
- 30. Tosoh AIA-Series
- 31. Vital Diagnostics ATAC 8000
- 32. Vital Diagnostics Envoy
- C. Current and Emerging Technologies
 - 1. Monoclonal and Polyclonal Antibodies
 - 2. Immunoassays
 - a. Technological Principle
 - b. Radioimmunoassay (RIA)
 - c. Enzyme Immunoassays (EIA)

Overview

ELISA

Immunofiltration

Particle-Membrane Capture Immunoassay

Enzyme Amplification

- d. Fluorescent Immunoassays
- e. Luminescence

Chemiluminescence

Bioluminescence

- f. Latex Agglutination
- g. Immunoprecipitation
- h. Affinity Chromatographu
- i. Liposome Flow-Injection Immunoassay
- 3. Molecular Diagnostics
 - a. Technology Overview
 - b. Amplification Methods

PCR

DAP-PCR

Immuno-PCR

QC-PCR

CAR

DNA

HPA

LCR

NASBA

QBR

SDA

- 3 SR, and others
- 4. Chromosome Analysis



- a. Chronic Myelogenous Leukemia (CML)
- b. Acute Myeloid Leukemia (AML)
- c. Acute Lymphoblastic Leukemia (ALL)
- d. Malignant LymphomasLymphoid Malignancies
- e. Chronic Lymphocytic Leukemia (CLL)
- f. Solid Cancers
- g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence
- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies
 - a. CT
 - b. MRI
- c. NMR
- d. PET
- e. Photonics Spectroscopy
- E. Personal Testing
- III. FRANCE: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS' SALES AND MARKET SHARES
- IV. GERMANY: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS' SALES AND MARKET SHARES
- V. ITALY: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT
- VI. JAPAN: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS' SALES AND MARKET SHARES
- VII. SPAIN: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS' SALES AND MARKET SHARES
- VIII. U.K.: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT
- IX. U.S.A.: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS' SALES AND



MARKET SHARES

X. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

XI. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
 - 1. Marketing Approaches
 - 2. Product Complexity
 - 3. Customer Preference
 - 4. Established Suppliers
 - 5. Emerging Suppliers
 - 6. Major Types of Distributors
 - 7. Market Segmentation Factor

XII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

XIII. COMPETITIVE PROFILES

Abbott

AdnaGen

Applied Gene Technologies

Arca Biopharma

Beckman Coulter/Danaher

Becton Dickinson

Biomedical Diagnostics

bioMerieux

Bio-Rad



Cepheid

Correlogic Systems

Decode Genetics

Diadexus

Diagnocure

Diasorin

Eiken Chemical

Elitech Group

Enterix

Enzo Biochem

Epigenomics

Exact Sciences

Fujirebio

Hologic/Gen-Probe

Guided Therapeutics

Kreatech/Leica

Kyowa Medex

Mackay Life Sciences

Myriad Genetics

OncoLab

Ortho-Clinical Diagnostics

Panacea Pharmaceuticals

Polartechnics

Polymedco

PreMD

Qiagen

Quest Diagnostics

Radient Pharmaceuticals

Roche

Scienion

Sequenom

Siemens Healthcare

Takara Bio

Targeted Diagnostics & Therapeutics

Thermo Fisher

Tosoh

Veridex

Wako Pure Chemicals

Wallac/PE



Zila



List Of Tables

LIST OF TABLES

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

France CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment

France CA 19-9 Test Volume and Diagnostics Sales by Market Segment

France CA 125 Test Volume and Diagnostics Sales by Market Segment

France CA 15-3/27.29 Testing Market by Major Supplier

France CA 19-9 Testing Market by Major Supplier

France CA 125 Testing Market by Major Supplier

Germany CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment

Germany CA 19-9 Test Volume and Diagnostics Sales by Market Segment

Germany CA 125 Test Volume and Diagnostics Sales by Market Segment

Germany CA 15-3/27.29 Testing Market by Major Supplier

Germany CA 19-9 Testing Market by Major Supplier

Germany CA 125 Testing Market by Major Supplier

Italy CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment

Italy CA 19-9 Test Volume and Diagnostics Sales by Market Segment

Italy CA 125 Test Volume and Diagnostics Sales by Market Segment

Japan CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment

Japan CA 19-9 Test Volume and Diagnostics Sales by Market Segment

Japan CA 125 Test Volume and Diagnostics Sales by Market Segment

Japan CA 15-3/27.29 Testing Market by Major Supplier

Japan CA 19-9 Testing Market by Major Supplier

Japan CA 125 Testing Market by Major Supplier

Spain CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment

Spain CA 19-9 Test Volume and Diagnostics Sales by Market Segment

Spain CA 125 Test Volume and Diagnostics Sales by Market Segment

Spain CA 15-3/27.29 Testing Market by Major Supplier

Spain CA 19-9 Testing Market by Major Supplier

Spain CA 125 Testing Market by Major Supplier

U.K. CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment

U.K. CA 19-9 Test Volume and Diagnostics Sales by Market Segment

U.K. CA 125 Test Volume and Diagnostics Sales by Market Segment

U.S.A. CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment

U.S.A. CA 19-9 Test Volume and Diagnostics Sales by Market Segment



U.S.A. CA 125 Test Volume and Diagnostics Sales by Market Segment

U.S.A. CA 15-3/27.29 Testing Market by Major Supplier

U.S.A. CA 19-9 Testing Market by Major Supplier

U.S.A. CA 125 Testing Market by Major Supplier



I would like to order

Product name: 2016 Emerging Opportunities in the CA Tumor Marker Testing Market

Product link: https://marketpublishers.com/r/2B68CD28609EN.html

Price: US\$ 4,360.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/2B68CD28609EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970